Old drugs, new uses: Drug repurposing in hematological malignancies

Discovery and development of novel anti-cancer drugs are expensive and time consuming. Systems biology approaches have revealed that a drug being developed for a non-cancer indication can hit other targets as well, which play critical roles in cancer progression. Since drugs for non-cancer indicatio...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2021-01, Vol.68, p.242-248
Main Authors: Kale, Vijay P., Habib, Hasan, Chitren, Robert, Patel, Milan, Pramanik, Kartick C., Jonnalagadda, Subash C., Challagundla, Kishore, Pandey, Manoj K.
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Drug development
Drug Discovery
Drug repositioning
Drug Repositioning - methods
Drug repurposing
Hematologic Neoplasms - drug therapy
Hematological malignancies
Humans
Multiple myeloma
Pharmaceutical Preparations - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Discovery and development of novel anti-cancer drugs are expensive and time consuming. Systems biology approaches have revealed that a drug being developed for a non-cancer indication can hit other targets as well, which play critical roles in cancer progression. Since drugs for non-cancer indications would have already gone through the preclinical and partial or full clinical development, repurposing such drugs for hematological malignancies would cost much less, and drastically reduce the development time, which is evident in case of thalidomide. Here, we have reviewed some of the drugs for their potential to repurpose for treating the hematological malignancies. We have also enlisted resources that can be helpful in drug repurposing.
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2020.03.005